Clinical Trial Update: Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures [Phase 2]

View source ↗

Summary

Phase 2 trial update on long-term safety of pharmaceutical-grade synthetic cannabidiol oral solution in pediatric patients with treatment-resistant childhood ab…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Childhood Absence Epilepsy

Drugs mentioned

• synthetic cannabidiol oral solution (synthetic cannabidiol)

Snippet

Sponsor: Radius Pharmaceuticals, Inc. | Conditions: Childhood Absence Epilepsy | Phase 2 | Status: TERMINATED | Results posted: 2023-06-18